Nautilus Biotechnology, Inc. (NAUT)

NASDAQ: NAUT · IEX Real-Time Price · USD
2.94
+0.10 (3.52%)
At close: Aug 11, 2022 4:00 PM
3.08
+0.14 (4.76%)
After-hours: Aug 11, 2022 7:35 PM EDT
3.52%
Market Cap 366.51M
Revenue (ttm) n/a
Net Income (ttm) -61.65M
Shares Out 124.66M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 512,591
Open 2.82
Previous Close 2.84
Day's Range 2.82 - 3.29
52-Week Range 2.53 - 8.61
Beta 0.79
Analysts Buy
Price Target 7.82 (+166.0%)
Earnings Date Aug 2, 2022

About NAUT

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington. [Read more...]

Industry Biotechnology
Founded 2016
Employees 124
Stock Exchange NASDAQ
Ticker Symbol NAUT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for NAUT stock is "Buy." The 12-month stock price forecast is 7.82, which is an increase of 165.99% from the latest price.

Price Target
$7.82
(165.99% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Nautilus Biotechnology Reports Second Quarter 2022 Financial Results

SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis, today reported financial results for the ...

Nautilus Biotechnology to Announce Second Quarter 2022 Financial Results on August 2, 2022

SEATTLE, July 13, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, toda...

Nautilus Biotechnology Reports First Quarter 2022 Financial Results

SEATTLE, May 03, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis, today reported financial results for the f...

Nautilus Biotechnology to Announce First Quarter 2022 Financial Results on May 3, 2022

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, tod...

Nautilus Biotechnology to Present at EuPA and AACR Meetings

• Co-founder and Chief Scientist Parag Mallick, Ph.D., to present lecture at Annual Congress of the European Proteomics Association (EuPA)  • Associate Director Greg Kapp, Ph.D., to present poster at Am...

Nautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors

Schrödinger President of R&D, Therapeutics brings extensive leadership in commercializing breakthrough biotechnologies to company developing platform for comprehensively quantifying the proteome to enab...

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results

SEATTLE, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results...

Nautilus to Participate in the 42nd Annual Cowen Health Care Conference

SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, toda...

Jim Cramer considers the investment cases for Nautilus Biotechnology and Cyxtera Technologies

On Friday's episode of "Mad Money," host Jim Cramer reviewed the investment cases for Nautilus Biotechnology and Cyxtera Technologies, two companies that viewers had previously called about in search of...

Other symbols: CYXT

Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome

SEATTLE and CAMBRIDGE, England, Nov. 2, 2021 /PRNewswire/ -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying ...

Other symbols: ABCM

Nautilus Biotechnology Reports Third Quarter 2021 Financial Results

SEATTLE, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, toda...

Nautilus Biotechnology to Announce Third Quarter of Fiscal Year 2021 Financial Results on November 2, 2021

SEATTLE, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, toda...

Nautilus to Participate in the Morgan Stanley Global Healthcare Conference

SEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteom...

Nautilus Biotechnology Reports Second Quarter 2021 Financial Results

SEATTLE, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a life sciences company creating a platform technology for quantifying and unlocking the complexity...

Nautilus Biotechnology Appoints Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development

Former Pacific Biosciences executive brings deep expertise in single-molecule analysis to large-scale platform designed to comprehensively quantify the proteome Former Pacific Biosciences executive brin...

Why Nautilus Biotechnology (NAUT) Stock Trading Higher Thursday?

Nautilus Biotechnology Inc (NASDAQ: NAUT) shares are trading higher during mid-day trading on Thursday following a CNBC report that Amazon.com Inc (NASDAQ: AMZN) held around $15 million stake in the com...

Nautilus Biotechnology soars 65% after Amazon reveals a $15 million stake in the small-cap company

Nautilus is developing a platform that works to measure and identify the complexities of proteins, which could lead to drug discoveries.

Nautilus Biotechnology shares surge 50% on news of Amazon investment

Shares of Nautilus Biotechnology rose by as much as 50% on Thursday morning after a report revealed that Amazon has taken an equity stake in the newly public Seattle-based company.

Other symbols: AMZN

Amazon discloses investment in biotech firm Nautilus

CNBC's Dominic Chu reports on an Amazon invetment of $14.7 million in Nautilus, a pre-revenue biotech firm.

Other symbols: AMZN

Amazon invested millions in a pre-revenue company with a system for measuring human proteins

Amazon declined to specify whether it's working with Nautilus Technology in addition to investing. The online retailer has been pushing into health care.

Other symbols: AMZN

Nautilus Biotechnology to Announce Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021

SEATTLE, July 13, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, toda...

Sujal Patel-led Nautilus Biotechnology goes public as it tackles ambitious plan to analyze proteins

Nautilus Biotechnology is emerging as Seattle's newest publicly traded company this week, taking advantage of the mania over SPACs to raise $345 million to fuel a new approach that could accelerate biom...

Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Pro...

SEATTLE and NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the c...

ARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp III (“ARYA”) (Nasdaq: ARYA), today announced that, due to the public health and safety concerns related to the coronavirus (COV...

Nautilus Biotechnology Appoints Matt Murphy as General Counsel

SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)--Nautilus Biotechnology appoints Matt Murphy, former 10x Genomics and Pacific Biosciences executive, as General Counsel